BMAC – Biopharmaceutical Manufacturer's Advisory Council
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
As the biopharmaceutical industry has evolved over the past 2 decades, Lonza has matched its evolution. The newest addition to our Tuas plant’s cell culture production capability takes advantage of the benefits of single use technology (SUT). We have developed platform fermentation and purification processes which allows us to help customers reduce the time between development and full scale GMP production. The team routinely works with numerous customers to bring new processes and molecules to 2000 liter full-scale commercial fruition.
Lonza Singapore’s Cell Gene Technologies (CGT) operates multiple purpose-built GMP-qualified production suites for the manufacture of Cell Therapy products designated for clinical trials and commercial
Our Development Services Team performs laboratory work that enables our customers to create mammalian cell culture processes, used to produce novel therapeutic proteins.